Tactics And Training
Hemp-derived THC is the new Drug War boogeyman even the cannabis industry loves to hate
Hemp-derived THC is the new Drug War boogeyman even the cannabis industry loves to hate
📅
✍️By ZRIntel Editorial Team📍Washington, USA
On October 24, 39 state attorneys general sent a letter to congressional leaders urging them to close a loophole in federal law that has led to a burgeoning market for hemp-derived THC products. This market, which arose in the wake of the 2018 Farm Bill legalizing hemp farming, has, through clever exploitation of legal nuances, enabled the creation of a multibillion-dollar industry dedicated to producing hemp products that mimic the psychoactive effects of cannabis, all while skirting federal prohibitions and state regulations meant to govern the cannabis sector. The language used by the attorneys general in their letter echoes the reefer madness rhetoric often seen in America's historic Drug War: references are made to the Farm Bill being exploited by "bad actors" who are marketing "harmful products" to minors, prioritizing profits at the expense of public health. In response, many states have enacted local laws to clamp down on hemp-derived THC products. Washington, for instance, recently banned the sale of THC products by entities other than licensed cannabis retailers. Despite these regulations, Washingtonians can still conveniently order these products online for delivery, a privilege not enjoyed by the legal cannabis market which operates under stringent regulations. Interestingly, the opposition to hemp-derived THC products has gained traction within the legal cannabis industry itself. This coalition of industry insiders argues not from a moral standpoint, but rather from a financial one. To them, hemp-derived products represent a direct threat to their livelihood as they compete in a marketplace heavily regulated with significant overhead costs, which simply do not afflict those producing hemp-based THC. Furthermore, hemp-derived products escape the taxation applied to legal recreational marijuana, providing them an even greater financial advantage. The fiscal landscape for hemp-derived THC has drastically altered the dynamics of competitive bidding within states, especially as cannabis remains illegal in 24 states, some of which include significant markets like Texas and Florida where hemp-derived THC products thrive without repercussions. According to reports from Bloomberg, lobbying around hemp-derived THC products almost doubled last year. Advocates for hemp legality have corralled around Republican U.S. Senator Rand Paul from Kentuckya state heavily invested in growing hempwho has expressed an unwillingness to support any legislation that seeks to restrict hemp-derived THC sales. In fact, his home state has seen its acreage dedicated to hemp cultivation double in the past year, indicating a thriving agriculture sector eager to defend its turf. As this debate unfolds, it underscores the complexities of American drug policy, reflecting on not just the regulatory environment surrounding cannabis but also the evolving economic landscape that has positioned hemp-derived THC products at the forefront. This issue is emblematic of the ongoing struggle between financial interests and public health concerns concerning THC products and their marketing, particularly in a landscape where many adults and minors alike have access to these substances through non-regulated means. The implications are far-reaching. If the attorneys general achieve success in their congressional endeavor, it may significantly alter the availability of hemp-derived THC products and reframe the competition for legal cannabis growers. However, we must also grapple with the reality that while calls for regulation strengthen, there is an equally vocal and organized defense of hemp products, suggesting a tense standoff between shifting state governance and established market players.